Abbott Laboratories
ABT130.620USD
+0.120+0.09%
Close 04/30, 16:00（ET）Quotes delayed by 15 min
226.19BMarket Cap
16.88P/E TTM
More Details of Abbott Laboratories Company
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
Company Info
Company codeABT
Company nameAbbott Laboratories
IPO dateMar 01, 1937
Founded at1900
CEOMr. Robert B. Ford
Number of employees114000
Security typeOrdinary Share
Fiscal year-endMar 01
Address100 Abbott Park Road
CityABBOTT PARK
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code60064-3500
Phone12246676100
Websitehttps://www.abbott.com
Company codeABT
IPO dateMar 01, 1937
Founded at1900
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+0.02%
Mr. Hubert L. Allen
Mr. Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
191.90K
+3.84%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
133.77K
+6.42%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-0.82%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.88K
-1.63%
Mr. Philip P. Boudreau
Mr. Philip P. Boudreau
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
56.91K
+44.72%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
40.80K
+4.17%
Ms. Nancy Mckinstry
Ms. Nancy Mckinstry
Lead Independent Director
Lead Independent Director
38.72K
+4.41%
Ms. Sally E. Blount, Ph.D.
Ms. Sally E. Blount, Ph.D.
Independent Director
Independent Director
36.66K
+4.67%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+0.02%
Mr. Hubert L. Allen
Mr. Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
191.90K
+3.84%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
133.77K
+6.42%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-0.82%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.88K
-1.63%
Revenue Breakdown
Currency: USDUpdate time: Sun, Apr 6
Currency: USDUpdate time: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Diabetes Care
6.80B
16.22%
Core Laboratory
5.24B
12.48%
Adult Nutritionals
4.39B
10.46%
Pediatric Nutritionals
4.02B
9.59%
Key Emerging Markets
3.86B
9.20%
Other
17.64B
42.05%
By RegionUSD
Name
Revenue
Proportion
United States
16.32B
38.91%
All other Countries
14.85B
35.39%
Germany
2.54B
6.05%
China
2.11B
5.04%
India
1.82B
4.33%
Other
4.31B
10.28%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Diabetes Care
6.80B
16.22%
Core Laboratory
5.24B
12.48%
Adult Nutritionals
4.39B
10.46%
Pediatric Nutritionals
4.02B
9.59%
Key Emerging Markets
3.86B
9.20%
Other
17.64B
42.05%
Shareholder
Update time: Sun, Feb 9
Update time: Sun, Feb 9
Shareholder Statistics
Type
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
9.68%
BlackRock Institutional Trust Company, N.A.
5.02%
State Street Global Advisors (US)
4.45%
Capital International Investors
3.92%
Capital Research Global Investors
3.12%
Other
73.81%
Shareholder Statistics
Shareholder
Proportion
The Vanguard Group, Inc.
9.68%
BlackRock Institutional Trust Company, N.A.
5.02%
State Street Global Advisors (US)
4.45%
Capital International Investors
3.92%
Capital Research Global Investors
3.12%
Other
73.81%
Type
Shareholder
Proportion
Investment Advisor
35.63%
Investment Advisor/Hedge Fund
32.73%
Research Firm
3.15%
Pension Fund
2.28%
Bank and Trust
2.13%
Sovereign Wealth Fund
1.31%
Insurance Company
0.99%
Hedge Fund
0.89%
Individual Investor
0.48%
Other
20.41%
Institutional Shareholding
Update time: Sun, Jan 19
Update time: Sun, Jan 19
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q1
4527
1.39B
80.29%
+21.54M
2024Q4
4535
1.39B
80.22%
+15.89M
2024Q3
4391
1.36B
78.29%
-11.85M
2024Q2
4400
1.36B
78.24%
-7.03M
2024Q1
4402
1.35B
77.67%
-9.71M
2023Q4
4429
1.35B
77.56%
-11.05M
2023Q3
4298
1.34B
77.39%
-25.33M
2023Q2
4297
1.35B
77.60%
-13.55M
2023Q1
4281
1.35B
77.46%
-8.61M
2022Q4
4258
1.34B
76.84%
-15.37M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
167.89M
9.68%
+762.54K
+0.46%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
87.07M
5.02%
+811.85K
+0.94%
Dec 31, 2024
State Street Global Advisors (US)
77.17M
4.45%
+447.25K
+0.58%
Dec 31, 2024
Capital International Investors
67.97M
3.92%
+2.23M
+3.39%
Dec 31, 2024
Capital Research Global Investors
54.10M
3.12%
+795.07K
+1.49%
Dec 31, 2024
Geode Capital Management, L.L.C.
35.67M
2.06%
+765.64K
+2.19%
Dec 31, 2024
Wellington Management Company, LLP
26.39M
1.52%
+581.33K
+2.25%
Dec 31, 2024
JP Morgan Asset Management
25.13M
1.45%
+5.11M
+25.51%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
20.98M
1.21%
+626.72K
+3.08%
Dec 31, 2024
Wells Fargo Advisors
15.25M
0.88%
-105.40K
-0.69%
Dec 31, 2024
View more
Related ETFs
Update time: Sat, Apr 5
Update time: Sat, Apr 5
Name
Proportion
iShares U.S. Medical Devices ETF
17.41%
Invesco Pharmaceuticals ETF
5.78%
Goldman Sachs Future Health Care Equity ETF
5.19%
NYLI Healthy Hearts ETF
4.78%
Polen Capital Global Growth ETF
4.77%
AdvisorShares Focused Equity ETF
4.63%
Proshares Ultra Health Care
4.32%
Health Care Select Sector SPDR Fund
4.24%
iShares U.S. Healthcare ETF
4.15%
Fidelity MSCI Health Care Index ETF
3.85%
View more
iShares U.S. Medical Devices ETF
Proportion17.41%
Invesco Pharmaceuticals ETF
Proportion5.78%
Goldman Sachs Future Health Care Equity ETF
Proportion5.19%
NYLI Healthy Hearts ETF
Proportion4.78%
Polen Capital Global Growth ETF
Proportion4.77%
AdvisorShares Focused Equity ETF
Proportion4.63%
Proshares Ultra Health Care
Proportion4.32%
Health Care Select Sector SPDR Fund
Proportion4.24%
iShares U.S. Healthcare ETF
Proportion4.15%
Fidelity MSCI Health Care Index ETF
Proportion3.85%
Dividend
A total of
16.46B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Dec 13, 2024
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 19, 2024
ABT.NB Final Cash Dividend of gross USD 0.55 paid on Nov 15, 2024 going ex on Oct 15, 2024
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 15, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 16, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on May 15, 2024 going ex on Apr 12, 2024
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Dec 15, 2023
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Feb 15, 2024 going ex on Jan 11, 2024 with reinvestment option
Jan 12, 2024
Feb 15, 2024
Jan 11, 2024
Sep 21, 2023
ABT.NB Final Cash Dividend of gross USD 0.51 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option
Oct 13, 2023
Nov 15, 2023
Oct 12, 2023
Jun 09, 2023
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option
Jul 14, 2023
Aug 15, 2023
Jul 13, 2023
Feb 17, 2023
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option
Apr 14, 2023
May 15, 2023
Apr 13, 2023
Dec 09, 2022
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option
Jan 13, 2023
Feb 15, 2023
Jan 12, 2023
Sep 15, 2022
ABT.NB Final Cash Dividend of gross USD 0.47 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option
Oct 14, 2022
Nov 15, 2022
Oct 13, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data